Metrics as of 10/16/2026, 08:32 AM (Berlin time), refresh in progress.
Bicara Therapeutics Stock
Bicara Therapeutics Inc. Common Stock
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Claire Mazumdar Clemon
- Employees
- 103
- Market cap
- $1.2 B
- IPO
- 13/09/2024
Bicara Therapeutics Inc. is a biopharmaceutical firm in the clinical development phase headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically designed for solid tumors. At the forefront of its pipeline is ficerafusp alfa, a…
Company description based on the data provider's company data, AI-assisted, created on 17/10/2026. Not investment advice.
Bicara Therapeutics stock: price history
1D
+1.6%
1W
+2.1%
1M
-22.3%
6M
-26.4%
YTD
+4.7%
1Y
-6.3%
2Y
-11.9%
5Y
–
10Y
–
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~3% weaker price swings than usual
Ask the agents about Bicara Therapeutics
Analyst assessment of Bicara Therapeutics
PRICE TARGET LOW
US$20.00
CONSENSUS
US$32.57
MEDIAN
US$35.00
PRICE TARGET HIGH
US$42.00
0
STRONG BUY
6
BUY
3
HOLD
0
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 12/08/2026
Bicara Therapeutics stock metrics
P/E
-5.68
P/B
2.55
EV/EBITDA
-5.79
RETURN ON EQUITY
-11.8%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
55.8%
FLOAT SHARES
36,900,013
AVG. DAILY VOLUME (30D)
749,522
Insider transactions (SEC)
Cohlhepp Ryan
Cohlhepp Ryan
Cohlhepp Ryan
Hyep Ivan
Hyep Ivan
Institutional holders
Comparable stocks
Frequently asked questions about Bicara Therapeutics stock
What does Bicara Therapeutics do?
Bicara Therapeutics Inc. Common Stock is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Claire Mazumdar Clemon, the company employs around 103 people.
The IPO was on 13/09/2024; the stock trades on NASDAQ under the ticker BCAX.
What do analysts say about Bicara Therapeutics stock?
9 analysts rate the stock, the consensus is Buy (as of 12/08/2026).
The average price target is US$32.57, ranging from US$20.00 to US$42.00, with a median of US$35.00.
This is an external assessment, not a statement by Market Jury.
When does Bicara Therapeutics report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly -3% stronger than usual.
Does Bicara Therapeutics pay a dividend?
No, Bicara Therapeutics currently does not pay a dividend.
Which stocks are comparable to Bicara Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Bicara Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Bicara Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.